Acerus Pharmaceuti Stock Price, News & Analysis (OTCMKTS:TRLPF)

$0.21 0.00 (0.00 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$0.21
Today's Range$0.21 - $0.21
52-Week Range$0.08 - $0.40
VolumeN/A
Average Volume3,800 shs
Market Capitalization$45.67 million
P/E RatioN/A
Dividend YieldN/A
Beta2.72

About Acerus Pharmaceuti (OTCMKTS:TRLPF)

Acerus Pharmaceuti logoTrimel Pharmaceuticals Corporation is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men's health, women's health and respiratory medicine. The Corporation holds a license for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system. Natesto™, a product utilizing Trimel's licensed bioadhesive nasal gel technology, was approved for sale in the United States by the FDA in May 2014. It is the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Natesto™ is self-administered via a nasal applicator thereby minimizing the risk of secondary exposure to testosterone of women or children. Trimel is also developing Tefina™, a use-as-required testosterone nasal gel for the treatment of female orgasmic disorder. Tefina™ has completed a number of clinical studies, including a large Phase II trial in April 2014, where the product positively showed statistical significance and was found to be well-tolerated. In July 2014, Trimel acquired the Canadian rights to Estrace® (17-beta estradiol), a product indicated for the treatment of symptomatic relief of menopausal symptoms.

Receive TRLPF News and Ratings via Email

Sign-up to receive the latest news and ratings for TRLPF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:TRLPF
CUSIPN/A
Phone416-679-0771

Debt

Debt-to-Equity Ratio0.24%
Current Ratio1.62%
Quick Ratio0.84%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$24.49 million
Price / Sales1.86
Cash Flow$0.06 per share
Price / Cash3.44
Book Value$0.06 per share
Price / Book3.57

Profitability

Trailing EPS($0.03)
Net Income$11.11 million
Net Margins-103.61%
Return on Equity-64.41%
Return on Assets-27.39%

Miscellaneous

Employees17
Outstanding Shares213,120,000

Acerus Pharmaceuti (OTCMKTS:TRLPF) Frequently Asked Questions

What is Acerus Pharmaceuti's stock symbol?

Acerus Pharmaceuti trades on the OTCMKTS under the ticker symbol "TRLPF."

How were Acerus Pharmaceuti's earnings last quarter?

Acerus Pharmaceuti (OTCMKTS:TRLPF) issued its quarterly earnings data on Wednesday, March, 18th. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by $0.02. Acerus Pharmaceuti had a negative return on equity of 64.41% and a negative net margin of 103.61%. View Acerus Pharmaceuti's Earnings History.

When will Acerus Pharmaceuti make its next earnings announcement?

Acerus Pharmaceuti is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for Acerus Pharmaceuti.

Who are some of Acerus Pharmaceuti's key competitors?

How do I buy Acerus Pharmaceuti stock?

Shares of Acerus Pharmaceuti can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acerus Pharmaceuti's stock price today?

One share of Acerus Pharmaceuti stock can currently be purchased for approximately $0.21.

How big of a company is Acerus Pharmaceuti?

Acerus Pharmaceuti has a market capitalization of $45.67 million and generates $24.49 million in revenue each year. The specialty pharmaceutical company earns $11.11 million in net income (profit) each year or ($0.03) on an earnings per share basis. Acerus Pharmaceuti employs 17 workers across the globe.

How can I contact Acerus Pharmaceuti?

Acerus Pharmaceuti's mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The specialty pharmaceutical company can be reached via phone at 416-679-0771 or via email at [email protected]


MarketBeat Community Rating for Acerus Pharmaceuti (TRLPF)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  113
MarketBeat's community ratings are surveys of what our community members think about Acerus Pharmaceuti and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Acerus Pharmaceuti (OTCMKTS:TRLPF) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Acerus Pharmaceuti (OTCMKTS:TRLPF) Consensus Price Target History

Price Target History for Acerus Pharmaceuti (OTCMKTS:TRLPF)

Acerus Pharmaceuti (OTCMKTS:TRLPF) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
3/22/2017Roth CapitalReiterated RatingBuyView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Acerus Pharmaceuti (OTCMKTS:TRLPF) Earnings History and Estimates Chart

Earnings by Quarter for Acerus Pharmaceuti (OTCMKTS:TRLPF)

Acerus Pharmaceuti (OTCMKTS TRLPF) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018        
11/6/2017Q3 2017($0.01)$1.90 millionViewN/AView Earnings Details
8/11/2017Q2 2017($0.01)($0.01)$1.72 million$1.45 millionViewN/AView Earnings Details
5/12/2017Q1 2017($0.01)($0.01)$1.70 million$1.27 millionViewN/AView Earnings Details
8/8/2016Q2 2016$0.03$2.14 millionViewN/AView Earnings Details
5/4/2016Q1 2016($0.01)$0.03$2.05 million$10.41 millionViewN/AView Earnings Details
3/2/2016Q4 2015($0.01)$0.01$3.01 million$8.15 millionViewN/AView Earnings Details
11/4/2015Q3 2015($0.02)$0.01$3.05 million$2.82 millionViewN/AView Earnings Details
8/5/2015($0.01)($0.01)$2.52 million$2.74 millionViewN/AView Earnings Details
3/18/2015($0.02)($0.04)ViewN/AView Earnings Details
3/5/2015Q4 2014($0.02)($0.04)$2.20 million$2.57 millionViewN/AView Earnings Details
11/7/2014($0.02)($0.02)$1.75 million$1.75 millionViewN/AView Earnings Details
7/30/2014Q2 2014($0.05)ViewN/AView Earnings Details
6/17/2014($0.04)($0.02)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.04)($0.02)ViewN/AView Earnings Details
3/5/2014Q4 2013($0.04)($0.07)ViewN/AView Earnings Details
11/4/2013Q3 2013($0.04)($0.03)ViewN/AView Earnings Details
7/31/2013Q2 2013($0.04)($0.07)ViewN/AView Earnings Details
5/8/2013Q1 2013($0.04)($0.09)ViewN/AView Earnings Details
3/25/2013Q4 2012($0.04)($0.09)ViewN/AView Earnings Details
11/8/2012Q3 2012($0.04)($0.07)ViewN/AView Earnings Details
8/7/2012Q2 2012($0.04)($0.09)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.04)($0.08)ViewN/AView Earnings Details
3/9/2012Q4 2011($0.04)($0.06)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Acerus Pharmaceuti (OTCMKTS:TRLPF) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Acerus Pharmaceuti (OTCMKTS:TRLPF)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Acerus Pharmaceuti (OTCMKTS TRLPF)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Acerus Pharmaceuti (OTCMKTS TRLPF) News Headlines

Source:
DateHeadline
Trimel Pharmaceuticals (TRLPF) Cut to "Sell" at ValuEngineTrimel Pharmaceuticals (TRLPF) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - December 3 at 6:30 AM
Trimel Pharmaceuticals Corp. (TRLPF) Raised to "Hold" at ValuEngineTrimel Pharmaceuticals Corp. (TRLPF) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - November 28 at 12:36 AM
Trimel reports 3Q lossTrimel reports 3Q loss
finance.yahoo.com - November 7 at 12:21 PM
Trimel Pharmaceuticals Corp. (TRLPF) to Release Earnings on TuesdayTrimel Pharmaceuticals Corp. (TRLPF) to Release Earnings on Tuesday
www.americanbankingnews.com - November 1 at 10:49 AM
Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF) to Release Earnings on FridayTrimel Pharmaceuticals Corp. (OTCMKTS:TRLPF) to Release Earnings on Friday
www.americanbankingnews.com - August 5 at 9:06 AM

SEC Filings

Acerus Pharmaceuti (OTCMKTS:TRLPF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Acerus Pharmaceuti (OTCMKTS TRLPF) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.